智通财经APP获悉，心泰医疗(02291)午前涨超18%，截至发稿，涨16.49%，报13.07港元，成交额5009.35万港元。
消息面上，7月，由心泰医疗自主研发的MemoSorb®生物可降解房间隔缺损(ASD)封堵器、全降解室间隔缺损(VSD)封堵器获批沙特阿拉伯医疗器械上市许可。早在4月，生物可降解卵圆孔未闭(PFO)封堵器、经导管植入式主动脉瓣膜系统(TAVR)已率先获批沙特上市许可。
据悉，沙特作为中东地区最大的医疗市场之一，其SFDA认证素以高标准、严要求着称，得到海湾合作委员会(GCC)国家及周边市场的广泛认可。此次获批意味着心泰医疗以MemoSorb®PFO/ASD/VSD封堵器矩阵+ScienCrown®TAVR系统为核心的结构性心脏病方案体系全面落地中东市场，获得海外权威监管认可，为后续中东地区临床应用、服务全球更多心血管疾病患者奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.